Korean Ministry of Health and Welfare, International Vaccine Institute (IVI) sign agreement on vaccine development and delivery cooperation

2017-04-04 04:56
- Agreement to collaborate on vaccine R&D projects, capacity-building, and information-exchange programs between IVI, universities, research institutes and industry

- IVI Director General Jerome Kim thanks Korea for its support of global health R&D and vows to increase IVI’s cooperation with Korea

Dr. Chung Chin-youb (left), Minister of Health & Welfare, and Dr. Jerome Kim, Director General of the International Vaccine Institute after exchanging an MOU on bilateral cooperation at IVI headquarters in Seoul on April 3.

April 3,2017, SEOUL, KOREA - The Ministry of Health & Welfare of the Republic of Korea (MOH) and the International Vaccine Institute (IVI) signed a memorandum of understanding (MOU) on a collaboration to advance global public health, and to develop and deliver vaccines and related technologies for developing countries. Dr. Chung Chin-youb, Minister of Health & Welfare, visited the IVI headquarters at Seoul National University Research Park on April 3rd and exchanged the MOU with IVI Director General Dr. Jerome Kim, and discussed plans on mutual cooperation between Korea and the institute.

Established in 1997, IVI was the first international organization headquartered in Korea.  As IVI’s host country, Korea provides funding through its Official Development Assistance (ODA) to the institute for its vaccine research and operations. Up until recently, the institute was under the Ministry of Education. This MOU is a revision of the MOU signed in 2013 between the Ministry of Education and IVI, and includes newly added areas of support and expanded cooperation between IVI and MOH such as joint vaccine R&D projects and capacity-building initiatives.

Under the purview of MOH, IVI will continue to receive funding from the Korean government to support its operations as per the original host country agreement signed between IVI and Korea. The Ministry will also continue to support IVI's vaccine research and development activities to help the institute fulfill its mission of making safe, effective and affordable vaccines available for global health.

Finally IVI and the Ministry agreed to actively support exchange and cooperation programs in Korea by collaborating more with Korean universities, research institutes and the life sciences industry.  Notably, IVI and the Korean Centers for Disease Control will partner to develop vaccines against norovirus and hepatitis A.

IVI has a proven track record of partnering with Korean companies on vaccine development and commercialization for the global public health market. It transferred the oral cholera vaccine technology to the bio-venture company EuBiologics, and their oral cholera vaccine (Euvichol) is stockpiled by the World Health Organization (WHO) and used by United Nations agencies such as UNICEF.  IVI also developed a new typhoid conjugate vaccine, and transferred the technology to SK Chemicals.  The two organizations are currently conducting clinical trials in the Philippines with the intent of having the vaccine approved for global use by WHO.

"I would like to extend our profound gratitude to the Republic of Korea for its lasting commitment and generous support to IVI and to global health,” said IVI Director General Dr. Jerome Kim. “We look forward to being an essential international cooperation partner of Korea by working with Korean academia, industry and research institutes and helping them develop and deliver new and improved vaccines for the world.”

Dr. Chung Chin-youb (right), Minister of Health & Welfare, takes a guided tour to laboratories at the International Vaccine Institute on April 3rd after exchanging an MOU on bilateral cooperation with IVI Director General Dr. Jerome Kim

About IVI

The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, MERS-CoV, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit